Form 4: Crinetics Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On March 19, 2025, Dana Pizzuti, the Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold shares of the company's common stock.
• The sales were executed in two separate transactions to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) granted on March 1, 2023, and March 4, 2024.
• The first transaction involved the sale of 2,388 shares at a volume weighted average price of $34.17 per share, with prices ranging from $33.78 to $34.77.
• The second transaction involved the sale of 127 shares at a volume weighted average price of $34.83 per share, with prices ranging from $34.78 to $35.00.
• Following these transactions, Pizzuti directly owns 72,233 shares of Crinetics Pharmaceuticals common stock.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The document describes routine transactions related to executive compensation and tax obligations. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Insider sales are a common occurrence, especially to cover tax obligations related to equity compensation. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The share sales may have a minor dilutive effect on existing shareholders, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

Crinetics Pharmaceuticals, Dana Pizzuti, Form 4, share sale, insider trading, Rule 10b5-1, Restricted Stock Units, tax withholding, CRNX